Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  American Journal of Medicine

• Publication date

  1996-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-9343(97)89487-9PMID 8629674
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Remission after Syngeneic Bone Marrow Transplantation in a Patient with AL Amyloidosis

  1995cited by this paper
• Heart transplantation in AL amyloidosis

  1995cited by this paper
• Phase II trial of recombinant interferon alfa‐2 in the treatment of primary systemic amyloidosis

  1993cited by this paper
• Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey.

  1991cited by this paper
• Response rates and survival in primary systemic amyloidosis.

  1991cited by this paper
• Long Survival in Patients with Al Amyloidosis

  1991cited by this paper
• Phase II trial of alpha-tocopherol (vitamin E) in the treatment of primary systemic amyloidosis.

  1990cited by this paper
• Phase II trial of α‐tocopherol (vitamin E) in the treatment of primary systemic amyloidosis

  1990cited by this paper
• Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis.

  1990cited by this paper
• Amyloidosis of immunoglobulin origin: useful treatment?

  1990cited by this paper
• Colchicine therapy of the renal amyloidosis of ulcerative colitis.

  1988cited by this paper
• Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973).

  1987cited by this paper
• Treatment of AL amyloidosis with melphalan, prednisone, and colchicine.

  1986cited by this paper
• Melphalan may be a more potent leukemogen than cyclophosphamide.

  1986cited by this paper
• Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases.

  1986cited by this paper
• Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature.

  1986cited by this paper
• Analysis of Survival Data.

  1985cited by this paper
• Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine.

  1985cited by this paper
• Therapy of primary amyloidosis with melphalan and prednisone.

  1979cited by this paper
• Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone.

  1979cited by this paper
• A new design for randomized clinical trials.

  1979cited by this paper
• Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.

  1978cited by this paper
• The successful treatment of primary amyloidosis with intermittent chemotherapy.

  1978cited by this paper
• Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome.

  1975cited by this paper
• Amyloidosis: review of 236 cases.

  1975cited by this paper
• Patterns of amyloidosis and their association with plasma-cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins.

  1974cited by this paper
• Colchicine for familial Mediterranean fever.

  1972cited by this paper

• Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real‐world patients

  2026cites this paper
• A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis

  2025cites this paper
• Functions and Clinical Significance of Myocardial Cell-Derived Immunoglobulins.

  2024cites this paper
• Autologous stem cell transplantation in AL amyloidosis: Muddy waters.

  2024cites this paper
• Systemic Amyloidosis and Kidney Transplantation: An Update.

  2024cites this paper
• Cardiovascular toxicity from therapies for light chain amyloidosis

  2023cites this paper
• Lengua gigante condicionante de disfagia en paciente con amiloidosis de cadenas ligeras

  2023cites this paper
• Future Developments in Light Chain Amyloidosis Management.

  2022cites this paper
• Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group

  2022cites this paper
• Liver Biopsy-confirmed Primary Hepatic Amyloidosis with Only Jaundice As the Initial Symptom: An Autopsy Case Report

  2022cites this paper
• Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina

  2022cites this paper
• Heart Failure and Cardiomyopathies: CT and MR from Basics to Advanced Imaging

  2022cites this paper
• Beyond Survival in AL amyloidosis: Identifying and Satisfying Patients’ Needs

  2022cites this paper
• Advanced Case of Cardiac Amyloidosis Presents With Chronic Diarrhea

  2022cites this paper
• Amyloidosis and the Kidney: An Update.

  2022cites this paper
• Sequential Liver, Kidney, and Autologous Stem Cell Transplant for AL Amyloidosis: A Case Report.

  2021cites this paper
• Primary Restrictive, Infiltrative, and Storage Cardiomyopathies

  2021cites this paper
• Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study

  2021cites this paper
• Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis.

  2021cites this paper
• Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.

  2021cites this paper
• Laryngeal Amyloidosis: A Decadal Experience

  2021cites this paper
• The Auxiliary Role of Cardiac Magnetic Resonance Feature-Tracking Parameters in the Differentiation between Cardiac Amyloidosis and Constrictive Pericarditis

  2021cites this paper
• Retrospective analysis of autologous stem cell transplantation for AL amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.

  2021cites this paper
• Primary localized amyloidosis causing urethral stricture disease: a mimicker of urothelial carcinoma

  2021cites this paper
• Potential therapeutic applications of phytoconstituents as immunomodulators: Pre‐clinical and clinical evidences

  2021cites this paper
• Demonstration of Amyloid in Osteosarcoma

  2021cites this paper
• Acute ischemic stroke patient with cardiac involvement of light chain amyloidosis

  2020cites this paper
• Future Perspectives

  2020cites this paper
• Evaluating Prognosis in AL Amyloidosis

  2020cites this paper
• Kidney Transplantation in Systemic Amyloidosis

  2020cites this paper
• Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.

  2020cites this paper
• Accidental colchicine poisoning with fatal outcome after ingestion of meadow saffron (Colchicum autumnale L.) - Report of autopsy case

  2020cites this paper
• Conventional Therapy for Amyloid Light-Chain Amyloidosis

  2020cites this paper
• Myocardial amyloidosis following multiple myeloma in a 38-year-old female patient: A case report

  2020cites this paper
• Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis

  2020cites this paper
• AL Amyloidosis for the Cardiologist and Oncologist

  2019cites this paper
• Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology

  2019cites this paper
• Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.

  2019cites this paper
• Amylose digestive (foie exclu)

  2019cites this paper
• Amyloidosis and the lung

  2019cites this paper
• Characterizing cardiac involvement in amyloidosis using cardiovascular magnetic resonance diffusion tensor imaging

  2019cites this paper
• Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis

  2019cites this paper
• Amiloidosis

  2019cites this paper
• Crystal structure of 6aJL2-R24G light chain variable domain: Does crystal packing explain amyloid fibril formation?

  2019cites this paper
• Long-term outcome of kidney transplantation in AL amyloidosis.

  2019cites this paper
• Light Chain (AL) Amyloidosis and the Kidney

  2018cites this paper
• Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment

  2018cites this paper
• The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-Analysis

  2018cites this paper
• Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity

  2017cites this paper
• Chapter 116 – Amyloidosis

  2017cites this paper
• De behandeling van AL-amyloïdose in Nederland anno 2013:

  2017cites this paper
• A Comprehensive Review

  2017cites this paper
• Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light‐chain amyloidosis

  2016cites this paper
• Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL‐) Amyloidosis

  2016cites this paper
• AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.

  2016cites this paper
• Immunomodulatory drugs in AL amyloidosis.

  2016cites this paper
• Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement

  2016cites this paper
• Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy

  2016cites this paper
• Is there still a place for autologous stem cell transplantation in systemic AL amyloidosis with severe renal disease?

  2016cites this paper
• The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.

  2016cites this paper
• CME Information: Immunoglobulin Light Chain Amyloidosis: 2016 Update on Diagnosis, Prognosis, and Treatment

  2016cites this paper
• Colchicine in Renal Medicine: New Virtues of an Ancient Friend

  2016cites this paper
• Immunoglobulin Light Chain Systemic Amyloidosis.

  2016cites this paper
• Primarily isolated hepatic involvement of amyloidosis

  2016cites this paper
• CARDIOLOGÍA DEL ADULTO - PRESENTACIÓN DE CASOS

  2016cites this paper
• Cardiac Amyloidosis Presenting With Myocardial Ischemia: Case Report and Review Article

  2016cites this paper
• Multisystem diseases affecting the skin and eye.

  2016cites this paper
• Induction therapy pre‐autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation

  2016cites this paper
• Colchicine as an anti-inflammatory and cardioprotective agent

  2015cites this paper
• Malnutrition, pharmaconutrition and other considerations in AL amyloidosis, a rare disease with masquerading symptoms and usually delayed diagnosis.

  2015cites this paper
• Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.

  2015cites this paper
• Prion and prion-like diseases in animals.

  2015cites this paper
• Guidelines on the management of AL amyloidosis

  2015cites this paper
• Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement.

  2015cites this paper
• Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial

  2014cites this paper
• Hepatomegaly, weight loss and general malaise – the first manifestations of primary systemic amyloidosis

  2014influential citation
• Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy.

  2014cites this paper
• Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

  2014cites this paper
• Light Chain Amyloidosis 2014

  2014cites this paper
• CME Information: Immunoglobulin Light Chain Amyloidosis: 2014 Update on Diagnosis, Prognosis, and Treatment

  2014cites this paper
• Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution

  2014cites this paper
• An evaluation of current treatment options for immunoglobulin light-chain amyloidosis

  2014cites this paper
• Patients of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment

  2013cites this paper
• AL amyloidosis Sequential heart and autologous stem cell transplantation for systemic

  2013cites this paper
• results of a phase II trial Lenalidomide and dexamethasone in the treatment of AL amyloidosis

  2013cites this paper
• Diagnosis and Management of Immunoglobulin Light Chain Amyloidosis

  2013cites this paper
• Acute myeloid leukemia: 2013 update on risk‐stratification and management

  2013cites this paper
• New Insights and Modern Treatment of AL Amyloidosis

  2013cites this paper
• Light chain amyloidosis 2012: a new era

  2013cites this paper
• Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment

  2013cites this paper
• Immunoglobulin Light Chain Amyloidosis (Primary Amyloidosis)

  2013cites this paper
• contributions of Ig V L germ line gene use and clonal plasma cell burden The tropism of organ involvement in primary systemic amyloidosis

  2013cites this paper
• Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement

  2013cites this paper
• AL amyloidosis patients prognostic factor of first-year survival after stem cell transplantation in Excessive fluid accumulation during stem cell mobilization: a novel

  2013cites this paper
• Primary Systemic Amyloidosis

  2013cites this paper
• Clinical Remission of Renal Amyloidosis after Autologous Peripheral Blood Stem Cell Transplantation

  2013cites this paper
• Современные методы лечения AL амилоидоза: обзор литературы и собственные данные

  2013cites this paper
• Diagnosis and therapy of immunoglobulin light chain amyloidosis (AL amyloidosis)

  2013cites this paper
• Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report

  2012cites this paper
• AL Amyloidosis

  2012cites this paper